GenoMed CEO to Chair Conference on Cancer Drug R&D
GenoMed, Inc- ("the Company" or "GenoMed") (National Quotation Bureau’s Pink Sheets Symbol GMED), a St. Louis, Missouri-based medical genomics company, announced today that its CEO, David Moskowitz MD, has been asked to chair as well as speak at an upcoming conference on Cancer Drug Research and Development to be held in San Diego, November 20-21, 2003.
The conference, sponsored by GTCBIO (www.gtcbio.com) will bring together Directors of cancer research of major biotech companies, including Millenium, Chiron, and Oxigene. Large pharmaceutical companies such as Pfizer will also speak. Tony Hunter of the Salk Institute, a world-reknowned expert on tyrosine kinases, will be the keynote speaker.
Dr. Moskowitz will speak on the topic, "Is Angiotensin II Behind Most Cancers (Except Prostate)?"
Dr. Moskowitz said, “Using genomic epidemiology, we’ve found that all cancers except prostate cancer are associated with over-activity of angiotensin I-converting enzyme (‘ACE’). ACE makes angiotensin II, which is an excellent candidate to drive all cancers, since it promotes angiogenesis. Prostate cancer is almost the exception that proves the rule."
Dr. Moskowitz elaborated, "ACE inhibitors and angiotensin II receptor blockers (‘ARBs’) are safe and already clinically available to treat high blood pressure. I believe these drugs may be effective adjunctive treatment for cancer. For example, ACE inhibitors and ARBs are potent angiostatins in their own right, which should improve the efficacy of the angiostatins being developed against tumor blood vessels."
Dr. Moskowitz continued, "We have in our clinical trials a patient with unresectable pancreatic cancer who is still doing fine after more than 9 months taking an ACE inhibitor. I think inhibiting angiotensin II may delay the occurrence of cancer, and perhaps prevent it altogether, if started early enough."
Dr. Moskowitz ended by saying, “At GenoMed we are extremely gratified that GTCBIO considers our work credible enough to accord us the tremendous honor of chairing this conference. One couldn't ask for a more stellar group of scientists with whom to discuss our results."
About GenoMed
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the molecular pathways of disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company has applied for patents based on its finding that the ACE gene is associated with most common cancers (other than prostate cancer), as well as lymphomas and chronic leukemias. The Company is currently recruiting volunteers for clinical trials in all cancers except prostate cancer:
b2i.us
GenoMed has already proven that it can prevent kidney dialysis due to diabetes and high blood pressure, as well as greatly delay emphysema. GenoMed’s treatment approach, which is patent-pending, is the cornerstone of the Company’s Next Generation Disease ManagementTM program. If inhibiting angiotensin II can also be shown to delay or even prevent cancer, this too will be incorporated into the Company’s Clinical Outcomes Improvement ProgramTM (COIPTM). Patients with diabetes, high blood pressure, or emphysema can already subscribe to GenoMed’s COIPTM for $800 a year.
For questions, please contact Dave Moskowitz, tel. 314-977-0110, FAX 314-977-0042, email: dwmoskowitz@genomedics.com, or visit GenoMed at www.genomedics.com.
. |
